AltPep, Backed by Section32 and Lilly, Gets $53M to Catch and Treat Early Alzheimer’s

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more.


You may also like

Early Detection, and Treatment, for Alzheimer’s: Valerie Daggett on The Long Run
Alector, Staying Private for Now, Pulls in $133M for Alzheimer’s R&D